Evaxion to present phase‑2 biomarker data for personalized cancer vaccine EVX‑01 at SITC 2026
Evaxion A/S will disclose new biomarker results from its phase‑2 trial of the AI‑designed vaccine EVX‑01 in advanced melanoma at the Society for Immunotherapy of Cancer Annual Meeting in Phoenix on November 6‑7, 2026. The trial, which combined EVX‑01 with pembrolizumab, showed a 75% objective response rate, with 12 of 16 patients responding and four achieving complete responses. Eighty‑nine percent of the neoantigen targets elicited tumor‑specific immune responses, and the responses were sustained through three‑year follow‑up. Senior Scientist Mads Lausen will present the data in both an oral and a poster session.
Why it matters
The strong efficacy signals could boost investor confidence in EVX‑01 as Evaxion’s lead asset and may influence future partnership or licensing discussions. The data will also inform the company’s upcoming regulatory and commercial strategy for the vaccine.
Key facts
- 1The biomarker data will be presented at the SITC Annual Meeting in Phoenix, Arizona, on November 6 (oral) and November 7 (poster) 2026. investing.com
- 2Mads Lausen, Senior Scientist at Evaxion, is the presenter. investing.com
- 3The phase‑2 trial investigated EVX‑01 in advanced melanoma patients, each receiving a personalized vaccine designed with Evaxion’s AI platform. investing.com
- 4At two‑year follow‑up, the trial showed an Objective Response Rate of 75% (12 of 16 patients responded, four with complete response). investing.com
- 5Eighty‑nine percent of the EVX‑01 neoantigen targets triggered a tumor‑specific immune response. investing.com
- 6Patients received EVX‑01 together with pembrolizumab for the first two years; a subset received EVX‑01 alone in the third year. finanznachrichten.de
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.